Epidemiological study of unknown primary melanoma patients from the French national melanoma database RIC-Mel.
Émilie Varey(Inserm), Brigitte Dréno(Nantes Université), P. Celérier(Roche (France)), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac‐Rat(Centre Hospitalier du Mans), A. Dupuy(Université de Rennes), Jean‐Michel Nguyen(Inserm), E. Maubec(Inserm), F. Skowron, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), B. Guillot(Université de Montpellier), P. Combemale(Centre Léon Bérard), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Amir Khammari(Inserm), B. Crickx(Assistance Publique – Hôpitaux de Paris)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k